Finch Therapeutics to Participate in the Jefferies Microbiome-Based Therapeutics Summit
On April 15, 2021, Finch Therapeutics (Nasdaq: FNCH) announced that CEO Mark Smith, PhD, will participate in the Jefferies Microbiome-Based Therapeutics Summit on April 22, 2021. The event includes a fireside chat and panel discussion, with a recording available on the Finch website post-event. Finch is a clinical-stage company specializing in microbiome therapeutics, notably its lead candidate CP101 for recurrent C. difficile infections, which is in late-stage trials. CP101 has received Breakthrough Therapy and Fast Track designations from the FDA.
- None.
- None.
SOMERVILLE, Mass., April 15, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs, today announced that Mark Smith, PhD, Chief Executive Officer, will participate in a fireside chat and panel discussion at the virtual Jefferies Microbiome-Based Therapeutics Summit on April 22, 2021.
A recording of the fireside chat will be available under the ‘Investors & News’ section of the Finch website on April 22, 2021. An archived replay will be accessible for 30 days following the event.
About Finch Therapeutics
Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs. With the capabilities to develop both complete and targeted microbiome therapeutics, Finch is advancing a rich pipeline of candidates designed to address a wide range of unmet medical needs. Finch’s lead candidate, CP101, is in late-stage clinical development for the prevention of recurrent C. difficile infection (CDI), and has received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration. In June 2020, Finch announced that CP101 met its primary efficacy endpoint in PRISM3, the first of two pivotal trials to support the development of CP101 for the prevention of recurrent CDI. Finch plans to initiate a Phase 3 trial, referred to as PRISM4, as its second pivotal trial of CP101 for recurrent CDI. Finch is also developing CP101 for the treatment of chronic hepatitis B virus, and FIN-211 for the treatment of the gastrointestinal and behavioral symptoms of autism spectrum disorder. In partnership with Takeda, Finch is advancing FIN-524 and FIN-525 for the treatment of ulcerative colitis and Crohn’s disease, respectively.
Media Contact:
Gabriella Linville-Engler
media@finchtherapeutics.com
Investor Contact:
Greg Perry
ir@finchtherapeutics.com
FAQ
What event will Finch Therapeutics participate in on April 22, 2021?
Who will represent Finch Therapeutics at the Jefferies Summit?
How can I access the recording of Finch's event?
What is Finch Therapeutics' lead candidate?
What designations has CP101 received from the FDA?
What other conditions is Finch Therapeutics developing treatments for?
